JP2013507423A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507423A5
JP2013507423A5 JP2012533614A JP2012533614A JP2013507423A5 JP 2013507423 A5 JP2013507423 A5 JP 2013507423A5 JP 2012533614 A JP2012533614 A JP 2012533614A JP 2012533614 A JP2012533614 A JP 2012533614A JP 2013507423 A5 JP2013507423 A5 JP 2013507423A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
alkylene
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507423A (ja
JP5624148B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/065300 external-priority patent/WO2011045330A1/en
Publication of JP2013507423A publication Critical patent/JP2013507423A/ja
Publication of JP2013507423A5 publication Critical patent/JP2013507423A5/ja
Application granted granted Critical
Publication of JP5624148B2 publication Critical patent/JP5624148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533614A 2009-10-13 2010-10-13 大環状インテグラーゼ阻害剤 Active JP5624148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172853 2009-10-13
EP09172853.5 2009-10-13
PCT/EP2010/065300 WO2011045330A1 (en) 2009-10-13 2010-10-13 Macrocyclic integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2013507423A JP2013507423A (ja) 2013-03-04
JP2013507423A5 true JP2013507423A5 (https=) 2013-11-21
JP5624148B2 JP5624148B2 (ja) 2014-11-12

Family

ID=41720665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012533614A Active JP5624148B2 (ja) 2009-10-13 2010-10-13 大環状インテグラーゼ阻害剤

Country Status (15)

Country Link
US (1) US8497270B2 (https=)
EP (1) EP2488521B1 (https=)
JP (1) JP5624148B2 (https=)
KR (1) KR20120087916A (https=)
CN (1) CN102574854B (https=)
AU (1) AU2010305805B2 (https=)
BR (1) BR112012008586A2 (https=)
CA (1) CA2777664C (https=)
EA (1) EA019558B1 (https=)
ES (1) ES2446720T3 (https=)
IL (1) IL218845A0 (https=)
MX (1) MX2012004426A (https=)
NZ (1) NZ598766A (https=)
WO (1) WO2011045330A1 (https=)
ZA (1) ZA201202516B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487176A1 (en) * 2011-02-14 2012-08-15 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
WO2014008636A1 (en) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
RS56701B1 (sr) 2013-05-17 2018-03-30 Merck Sharp & Dohme Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze
EP3008044B1 (en) 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
UA117499C2 (uk) 2013-09-27 2018-08-10 Мерк Шарп Енд Доум Корп. Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CA3042314A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
CN112358477A (zh) * 2020-11-10 2021-02-12 牡丹江医学院 一种用于治疗胆囊炎的药物及其制备方法
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115974886A (zh) * 2022-11-22 2023-04-18 国科大杭州高等研究院 一种含有二氢苯并呋喃骨架的大环内酰胺化合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS210880B1 (cs) 1979-10-19 1982-01-29 Jiri Krepelka Substituované imidy kyselin 4-arylnaftalen-2,3-dikarboxylových
CS225002B1 (cs) 1980-12-12 1984-02-13 Krepelka Jiri Deriváty 9-fenyl-1H-benzo/f/isoindol-1,3-dionu a způsob jejich výroby
JPH04217684A (ja) 1990-05-30 1992-08-07 Shionogi & Co Ltd アルド−ス還元酵素阻害物質
EP0729950A4 (en) * 1994-09-13 2001-02-07 Kyowa Hakko Kogyo Kk ANTI-HIV MEDICINAL PRODUCTS
ATE345129T1 (de) 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
EP1326611B1 (en) 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
PL360944A1 (en) 2000-10-12 2004-09-20 Merck & Co, Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
SK2662004A3 (sk) 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
NZ540729A (en) 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
US6890942B2 (en) 2003-05-16 2005-05-10 Bristol-Myers Squibb Company Acyl sulfonamides as inhibitors of HIV integrase
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
KR101363875B1 (ko) 2005-04-28 2014-02-21 시오노기세야쿠 가부시키가이샤 Hiv 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
US20080214527A1 (en) * 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
MX2008005137A (es) * 2005-10-27 2008-09-29 Shionogi & Co Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa.
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US8318929B2 (en) * 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines

Similar Documents

Publication Publication Date Title
JP2013507423A5 (https=)
JP2011518833A5 (https=)
JP2010536766A5 (https=)
JP2012512863A5 (https=)
JP2013518107A5 (https=)
JP2009535462A5 (https=)
JP2012502037A5 (https=)
JP2011105738A5 (https=)
JP2009535358A5 (https=)
JP2015500843A5 (https=)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2011527299A5 (https=)
JP2013032389A5 (https=)
JP2013542247A5 (https=)
JP2009526034A5 (https=)
JP2012092103A5 (https=)
JP2010077141A5 (https=)
JP2006524660A5 (https=)
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
JP2014500861A5 (https=)
JP2007302689A5 (https=)
UY32644A (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
JP2020097577A5 (https=)
JP2012532883A5 (https=)
JP2013513607A5 (https=)